Resources > Cellular Reprogramming

Cellular Reprogramming

Cellular reprogramming is the process of directing cellular identity to produce a desired or therapeutically valuable cell type, often through induced pluripotency, differentiation or transdifferentiation. The potential to produce and maintain any cell type of interest has great clinical value, creating the opportunity to develop a scalable and functional cell source for ex vivo cell therapy development, and explore novel therapeutic modalities, such as in vivo reprogramming, for treating diseases with an unmet medical need.

The concept of cellular reprogramming is not a new one, since Conrad Waddington’s proposal of the epigenetic landscape in 1957, researchers have worked to determine the factors of controlling cell fate. These efforts proved fruitful in the publication of Shinya Yamanaka’s discovery of ‘Induction of Pluripotent Stem Cells (iPSCs) from Adult Human Fibroblasts by Defined Factors’ in 2007, Yamanaka’s research elucidated the means of generating any cell type via cellular reprogramming, but a reliance on experience led trial and error limited its broad application in the development of cell-based therapies.

View all resources 

Cellular Reprogramming

Novel cell reprogramming approaches, such as MOGRIFY® and epiMOGRIFY, build on this groundbreaking research by systematizing the discovery of the factors driving and maintaining cellular identity. Here we discuss these techniques and the application of cell reprogramming in the context of next-generation cell therapies and novel in vivo reprogramming therapies. 

Presentation
Translating Cellular Reprogramming into Efficacious and Scalable Cell Therapies for Immuno-Oncology
2021   |   Alessandra De Riva
Adoptive cell therapy has arisen as a novel treatment for B cell malignancies, however, its clinical and commercial success still presents considerable challenges in accessibility for patients and questions regarding ...
Peer-Reviewed Paper
Exploiting Epigenetics to Systematically Optimise Culture Conditions for Cellular Therapies
2021   |   Joachim Luginbühl, Rodrigo Santos
One of the main challenges of cell therapies is the maintenance and/or expansion of the required therapeutic phenotype in vitro. Moreover, to meet both the traceability and safety requirements for a clinical-...
Application Note
Defining Cell Culture Conditions to Drive Cell Identity and Scalability in Cell Therapy
2021   |   Aida Moreno-Moral, David Anderson
Pluripotent stem cells (PSCs) represent a valuable resource for the generation of cell types for treating these diseases. These include cardiomyocytes, pancreatic beta cells, and hepatocytes, which have therapeutic po...
Webinar
Webinar: The Epigenetics Approach to Driving Cell Identity and Scalability in Cell Therapy
2021   |   Zoe Hewitt, Owen Rackham, Rodrigo Santos
In the delivery of scalable cell therapies, there is a fundamental need to derive viable cells in vitro. In addition to developing cell cultures that mimic in vivo conditions for the maintenance of t...
Commentary
A new technology for direct cell reprogramming
2019   |   Julian Gough
Japanese scientist Shinya Yamanaka changed the course of cell therapy in 2007 when he showed that mature human cells could be induced into an embryonic-like state. The discovery of induced pluripotent stem (iPS) cells...
Commentary
Cell Conversion Shortcuts Mapped with Predictive System
2016   |   Julian Gough
In the cell-fate conversion landscape, the road less traveled is transdifferentiation, even though it is the straighter path between one cell type and another. The more circuitous route, up to pluripotency and then do...